biostudies-literatureZhu XYouth Fund of Changhai Hospital2263-2270https://www.ebi.ac.uk/biostudies/studies/S-EPMC5633558biostudies-literatureUnknown6(10)The role of stereotactic body radiation therapy for the elderly with advanced or medically inoperable pancreatic cancer was still debated. Therefore, we evaluated the value of stereotactic body radiation therapy and its association with survival of those patients. A total of 417 elderly patients were retrospectively reviewed from 2012 to 2015. Overall survival (OS), progression-free survival (PFS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and toxicities were analyzed. Prescription doses ranged from 30-46.8 Gy in 5-8 fractions. Median age was 73 years old. Median OS, PFS, LRFS, and DMFS were 10, 8, 10, and 9.5 months, respectively. One-year OS, PFS, LRFS, and DMFS rate were 35.5%, 18.2%, 26.6%, and 27.1%, respectively. Tumor stage and tumor response atCancer medicinePrognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer.PMC5633558CH201709Ju XLi FCao YFang FQing SZhang HZhu XCao FShen YJia ZfalsePrognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer.The role of stereotactic body radiation therapy for the elderly with advanced or medically inoperable pancreatic cancer was still debated. Therefore, we evaluated the value of stereotactic body radiation therapy and its association with survival of those patients. A total of 417 elderly patients were retrospectively reviewed from 2012 to 2015. Overall survival (OS), progression-free survival (PFS), local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and toxicities were analyzed. Prescription doses ranged from 30-46.8 Gy in 5-8 fractions. Median age was 73 years old. Median OS, PFS, LRFS, and DMFS were 10, 8, 10, and 9.5 months, respectively. One-year OS, PFS, LRFS, and DMFS rate were 35.5%, 18.2%, 26.6%, and 27.1%, respectively. Tumor stage and tumor response at2017-01-01T00:00:00Z2017 Oct2025-04-27T03:56:42.828Z2019-03-27T02:58:30ZS-EPMC56335582883441010.1002/cam4.1164